Exenatide Pivotal Studies (AMIGOs)

Time (weeks)

30

0

-4

4

Placebo Lead-in

Placebo 0.02 mL BID

Exenatide5 µg BID

Exenatide 10 µg BID

Placebo 0.02 mL BID

Placebo 0.04 mL BID

Exenatide 5 µg BID

• Randomized, triple-blind, placebo-controlled, multi-center study

• Exenatide or placebo added to maximally effective doses of metformin and/or SFU in patients with type 2 diabetes

Basic Study Design

Previous slide

Next slide

Back to first slide

View graphic version